Eylea - direct healthcare professional communication (DHPC)

aflibercept

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Eylea 40 mg/mL (aflibercept solution for intravitreal injection): Higher risk of intraocular pressure increase with the pre-filled syringe

Summary:

Direct Healthcare Professional Communication

Key facts

• Medicine name:
  Eylea
• Active substance:
  aflibercept
• Therapeutic area (MeSH):
  • Wet Macular Degeneration
  • Macular Edema
  • Diabetes Complications
• Procedure number:
  EMEA/H/C/002392/II/0068
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  S01LA05
• Dissemination date:
  15/04/2021